Blue Meanies

Metadata

Regulatory Status

United States

• DEA Schedule: Psilocybin and psilocin are Schedule I controlled substances. P. cyanescens is found in subtropical regions of the United States (Hawaii, Gulf Coast states, Florida). Possession constitutes a federal offense.
• Hawaii: The species is particularly associated with Hawaiian cattle pastures, where it was historically common. Hawaii enforces federal and state drug laws prohibiting psilocybin possession.
• State decriminalization: Oregon and Colorado psilocybin access frameworks apply to psilocybin generally and do not distinguish source species.

Southeast Asia

• Thailand: Psilocybin mushrooms grow naturally in many areas and have historical use in traditional contexts. Thailand decriminalized psilocybin for medical research in 2022, though recreational use remains prohibited. P. cyanescens is among the most commonly encountered species.
• Cambodia, Laos, Vietnam: P. cyanescens grows in pastoral environments. Legal enforcement varies; “happy pizza” and “mushroom shake” tourism has historically involved this and related species.
• Philippines: The species was first described from the Philippines (as Agaricus cyanescens by Berkeley & Broome, 1871). Psilocybin mushrooms are controlled substances.
• Indonesia, Bali: P. cyanescens is found on cattle dung; consumption is illegal under Indonesian drug laws, which carry severe penalties.

Australia and New Zealand

• Australia: Psilocybin rescheduled to Schedule 8 (2023) for authorized psychiatric use (synthetic psilocybin only). P. cyanescens is found in tropical and subtropical Australia, particularly Queensland.
• New Zealand: P. cyanescens is present. Psilocybin is a Class A controlled substance.

European Union

• Status: P. cyanescens is not naturally found in most of Europe (requires tropical/subtropical conditions) but may be cultivated indoors. Psilocybin is controlled across the EU.

Mexico and Central America

• Status: P. cyanescens occurs in tropical regions. Traditional use of psilocybin mushrooms in Mexico primarily involves Psilocybe species (particularly P. mexicana, P. aztecorum), but Panaeolus species have been documented in ethnomycological surveys.

Conditions & Indications

Primary: Treatment-Resistant Depression and Major Depressive Disorder (Psilocybin Evidence, Non-Species-Specific)

• Applicability: The psilocybin molecule produced by P. cyanescens is identical to that used in all clinical trials. Phase 2 and Phase 3 trials have demonstrated psilocybin efficacy for treatment-resistant depression (COMPASS Pathways) and major depressive disorder (Johns Hopkins, Usona Institute).
• Potency consideration: The extremely high psilocybin and psilocin content of P. cyanescens means that a clinically relevant psilocybin dose (25 mg) corresponds to a very small quantity of dried mushroom material (approximately 0.5—1.5 g), increasing the risk of accidental overdose when using unquantified wild material.
• No species-specific clinical data: No trial has used P. cyanescens-derived psilocybin.

Secondary: End-of-Life Anxiety, Substance Use Disorders

• As with all psilocybin-producing species, the clinical evidence for these indications derives from synthetic psilocybin trials (see Psilocybe cubensis monograph for detailed trial data).

Emerging/Preclinical

• Psilocin pharmacology: The unusually high psilocin-to-psilocybin ratio in P. cyanescens is pharmacologically noteworthy. Psilocin is the active dephosphorylated metabolite of psilocybin. A species naturally high in psilocin would theoretically produce faster onset of effects (bypassing the dephosphorylation step) and potentially different pharmacokinetics than species with higher psilocybin-to-psilocin ratios. This has not been systematically studied. [NEEDS-RESEARCH]
• Serotonin content: P. cyanescens contains detectable levels of serotonin (5-HT) itself. The oral bioavailability and pharmacological significance of dietary serotonin from mushroom ingestion is poorly understood, as serotonin is extensively metabolized by MAO in the gut wall and liver. [NEEDS-RESEARCH]
• Ethnomycological significance: Documentation of traditional and contemporary use of Panaeolus species in Southeast Asian and Pacific Island cultures is limited compared to the extensive Mesoamerican ethnomycological literature on Psilocybe species. This represents a significant gap in ethnomycological knowledge. [NEEDS-RESEARCH]

Mechanism of Action

Primary Mechanisms

1. 5-HT2A receptor agonism via psilocin: As with all psilocybin-containing mushrooms, the primary mechanism involves psilocin acting as a partial agonist at serotonin 5-HT2A receptors on cortical pyramidal neurons. Psilocybin is dephosphorylated to psilocin; however, P. cyanescens already contains substantial free psilocin, which may contribute to a faster onset of action.

2. Default mode network disruption: Psilocin decreases activity and functional connectivity within the default mode network, facilitating cognitive flexibility and disruption of rumination patterns associated with depression.

3. Neuroplasticity promotion: Psilocybin/psilocin increases BDNF levels and promotes dendritic spine growth and synaptogenesis in cortical neurons (Shao et al., 2021).

4. Increased global brain connectivity: The “entropic brain” state induced by psilocin allows cross-network communication and cognitive-emotional flexibility.

Secondary Mechanisms

• 5-HT2C, 5-HT1A receptor activity: Psilocin modulates multiple serotonin receptor subtypes.
• Anti-inflammatory effects: Psilocybin reduces TNF-alpha and IL-6 in preclinical models.
• Direct psilocin contribution: The high free psilocin content of P. cyanescens may produce a different pharmacokinetic profile compared to species with primarily psilocybin (which requires hepatic dephosphorylation). Free psilocin is more susceptible to oxidative degradation (accounting for the intense blue bruising reaction), and dried material may lose potency more rapidly than high-psilocybin/low-psilocin species. [UNCERTAIN]
• Bluing reaction chemistry: The intense blue bruising characteristic of P. cyanescens results from oxidative oligomerization of psilocin. This reaction, elucidated by Lenz et al. (2020), involves enzymatic oxidation of psilocin by a laccase to produce 5,5’-dihydroxy-4,4’-biindolyl quinone, a blue pigment. The intensity of bluing correlates with psilocin content and serves as a field identification feature.

Clinical Evidence Summary

Species-Specific Analytical Studies

Clinical Trial Evidence (Synthetic Psilocybin, Non-Species-Specific)

• See Psilocybe cubensis monograph for comprehensive clinical trial data. All psilocybin clinical evidence is derived from synthetic compound and applies to psilocybin regardless of biological source.

Evidence Limitations

• No species-specific clinical data: All therapeutic evidence is extrapolated from synthetic psilocybin trials.
• Extreme potency variability: Individual P. cyanescens specimens show large variations in alkaloid content, making dosing from wild-collected material particularly unreliable.
• Limited ethnomycological documentation: Traditional use patterns in Southeast Asian cultures are poorly documented compared to Mesoamerican Psilocybe use.
• Psilocin instability: The high free psilocin content makes dried P. cyanescens more susceptible to potency loss during storage compared to high-psilocybin species, complicating any standardization efforts.
• Taxonomic complexity: The genus Panaeolus has undergone significant taxonomic revision. Copelandia cyanescens (Singer) is now synonymized with Panaeolus cyanescens, but older literature may use either name. Some confusion exists with non-psilocybin Panaeolus species (e.g., P. foenisecii).

Safety Profile

General Assessment

The safety profile of P. cyanescens is governed by its psilocybin/psilocin content but is complicated by its extreme potency. The same low physiological toxicity that characterizes psilocybin applies: no confirmed deaths from psilocybin toxicity, very high estimated lethal dose, primary risks are psychological rather than physiological. However, the high concentration of active compounds significantly increases the risk of accidental overdose and intensely challenging experiences when consumed without precise quantification.

Contraindications

• Psychotic spectrum disorders: Absolute contraindication. Risk of precipitating psychotic episodes.
• Concurrent serotonergic medications: SSRIs/SNRIs may attenuate effects; MAOIs strictly contraindicated.
• Cardiovascular disease: Transient increases in heart rate and blood pressure.
• Pregnancy and lactation: Contraindicated.
• Minors: No safety data.

Drug Interactions

• SSRIs/SNRIs: Attenuate psilocybin effects; rare serotonin toxicity.
• MAOIs: Potentiate and prolong effects; elevated serotonin syndrome risk. Strictly contraindicated.
• Lithium: Seizure risk. Contraindicated.
• Stimulants: Increased cardiovascular stress.
• CYP2D6 inhibitors: Theoretical increase in psilocin exposure.

Side Effects

• Common: Headache, nausea (may be more pronounced with P. cyanescens due to coprophilous substrate), anxiety, emotional distress, fatigue.
• Occasional: Paranoia, confusion, elevated blood pressure, tachycardia.
• Rare: Prolonged psychotic symptoms, HPPD, suicidal ideation.
• Potency-specific risk: The extreme potency of P. cyanescens means that small errors in quantity (even 0.5 g of dried material) can result in dramatically different experiences, from sub-threshold to overwhelmingly intense. This is a significant practical safety concern.

Identification Hazards

• Misidentification risk: P. cyanescens is a relatively nondescript small to medium brown mushroom found on dung in tropical/subtropical grasslands. Potential confusion with:
  • Non-psychoactive Panaeolus species (P. papilionaceus, P. fimicola): Not toxic but produce no psychoactive effects.
  • Protostropharia semiglobata: Common dung-inhabiting species, non-psychoactive.
  • Various toxic Conocybe and Pholiotina species that may share dung-associated habitats.
• Blue bruising test: While the intense bluing reaction of P. cyanescens is a useful identification feature, some non-psychoactive species also bruise blue (e.g., Boletus species), and the absence of bluing does not exclude psilocybin content in all species.

Toxicology

• Acute toxicity: Very low for the psilocybin/psilocin component. Same favorable toxicological profile as other psilocybin mushrooms.
• Dependence potential: Very low. Rapid tachyphylaxis. No physical withdrawal.
• Neurotoxicity: No evidence at psychoactive doses.
• Coprophilous contamination risk: Growth on animal dung raises theoretical concerns about bacterial contamination (Salmonella, E. coli) in wild-collected specimens, particularly if consumed fresh or minimally processed.

Clinical Dosage

Important Legal Disclaimer

Panaeolus cyanescens is a controlled substance in virtually all jurisdictions. The following dosage information is provided for toxicological and forensic reference only, not as a therapeutic recommendation.

Alkaloid Content Reference

• Psilocybin concentration: 0.35—2.02% dry weight (highly variable)
• Psilocin concentration: 0.60—2.95% dry weight (notably high)
• Combined total tryptamine alkaloids: Up to approximately 5.0% dry weight in potent specimens
• Typical potency comparison: Approximately 2—5 times more potent than Psilocybe cubensis per unit dry weight

Equivalent Doses (Theoretical, Not Clinical Recommendations)

• Clinical trial equivalent (25 mg psilocybin): Approximately 0.5—1.5 g dried P. cyanescens, based on average total tryptamine content. The wide range reflects specimen variability.
• Comparison: The same 25 mg psilocybin dose requires approximately 3.5—5 g dried P. cubensis or 2.0—2.5 g dried P. semilanceata.

Critical Dosing Considerations

• Extreme potency: P. cyanescens is among the most potent psilocybin mushrooms known. Small quantities can produce intense effects. This substantially increases the risk of accidental overdose.
• High psilocin content: The elevated free psilocin may produce faster onset than species with predominantly psilocybin.
• Storage instability: Free psilocin oxidizes readily. Dried P. cyanescens may lose potency more rapidly than other species, and potency of stored material is unpredictable.
• Natural variability: Extreme specimen-to-specimen variability makes reliable dosing impossible without analytical quantification.
• No established safe dose outside clinical supervision for psychiatric indications.

Sources

• Stijve T, de Meijer AAR. Macromycetes from the state of Parana, Brazil. 4. The psychoactive species. Arq Biol Technol. 1993;36(2):313-329
• Gartz J. Biotransformation of tryptamine derivatives in mycelial cultures of Psilocybe. J Basic Microbiol. 1989;29(6):347-352
• Tsujikawa K, Kanamori T, Iwata Y, et al. Morphological and chemical analysis of magic mushrooms in Japan. Forensic Sci Int. 2003;138(1-3):85-90
• Stamets P. Psilocybin Mushrooms of the World: An Identification Guide. Ten Speed Press; 1996
• Gurevich LS. Indole derivatives in certain Panaeolus species from East Europe and Siberia. Mycol Res. 1993;97(2):251-254
• Lenz C, Wick J, Braga D, et al. Injury-triggered blueing reactions of Psilocybe “magic” mushrooms. Angew Chem Int Ed. 2020;59(4):1450-1454
• Shao LX, Liao C, Greber I, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109(16):2535-2544.e4
• Allen JW, Merlin MD, Jansen KLR. An ethnomycological review of psychoactive agarics in Australia and New Zealand. J Psychoactive Drugs. 1991;23(1):39-69
• Heim R, Wasson RG. Les Champignons Hallucinogenes du Mexique. Editions du Museum National d’Histoire Naturelle; 1958
• Gerhardt E. Taxonomische Revision der Gattungen Panaeolus und Panaeolina (Fungi, Agaricales, Coprinaceae). Bibl Bot. 1996;147:1-149
• Nichols DE. Psilocybin: from ancient magic to modern medicine. J Antibiot (Tokyo). 2020;73(10):679-686
• Gotvaldova K, Hajkova K, Borovicka J, et al. Stability of psilocybin and its four analogs in the biomass of the psychotropic mushroom Psilocybe cubensis. Drug Test Anal. 2021;13(2):439-446

Connections

• Psilocybe cubensis: Psilocybe cubensis is the most widely studied psilocybin mushroom and the primary basis for clinical evidence. P. cyanescens (Panaeolus) contains substantially higher tryptamine alkaloid concentrations (2—5x per unit dry weight), particularly free psilocin. Both are coprophilous tropical/subtropical species, though they belong to different families (Bolbitiaceae vs. Hymenogastraceae), representing independent evolution of psilocybin biosynthesis.
• Psilocybin biosynthetic convergence: The psilocybin biosynthetic gene cluster (psiD, psiK, psiM, psiH) has been shown to have been horizontally transferred between distantly related fungal lineages. Panaeolus cyanescens and Psilocybe species acquired psilocybin production independently through horizontal gene transfer events, representing a remarkable case of convergent biochemical evolution across fungal families.
• Amanita muscaria: Fly Agaric provides a pharmacological contrast — GABA-A agonism (muscimol) vs. 5-HT2A agonism (psilocin), producing fundamentally different subjective experiences (sedative-dissociative vs. psychedelic).
• Ergot alkaloids: Claviceps purpurea produces ergot alkaloids including lysergic acid (precursor to LSD), another class of indole-derived serotonergic compounds from fungi. The convergent production of serotonin receptor-active indoles across diverse fungal lineages is a notable pattern in fungal chemical ecology.
• Potency context: Within the spectrum of psilocybin-producing species covered in this reference, P. cyanescens represents the high-potency extreme. This has practical implications for harm reduction: the margin for dosing error is significantly smaller with P. cyanescens than with lower-potency species.